Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients

[1]  Michael M Gottesman,et al.  A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. , 2009, Biochimica et biophysica acta.

[2]  V. Kristensen,et al.  Single nucleotide polymorphisms in the multidrug resistance gene 1 (ABCB1): effects on its expression and clinicopathological characteristics in breast cancer patients , 2008, Pharmacogenetics and genomics.

[3]  T. Aoki,et al.  Correlation of polymorphism C3435T of the MDR-1 gene and the response of primary chemotherapy in women with locally advanced breast cancer. , 2008, Genetics and molecular research : GMR.

[4]  G. Rosner,et al.  A Comparison of the Pharmacokinetics and Pharmacodynamics of Docetaxel between African-American and Caucasian Cancer Patients: CALGB 9871 , 2007, Clinical Cancer Research.

[5]  J. Keelan,et al.  Independent Regulation of Apical and Basolateral Drug Transporter Expression and Function in Placental Trophoblasts by Cytokines, Steroids, and Growth Factors , 2007, Drug Metabolism and Disposition.

[6]  Lippincott-Schwartz,et al.  Supporting Online Material Materials and Methods Som Text Figs. S1 to S8 Table S1 Movies S1 to S3 a " Silent " Polymorphism in the Mdr1 Gene Changes Substrate Specificity Corrected 30 November 2007; See Last Page , 2022 .

[7]  W. M. Smit,et al.  Pharmacogenetic Screening of CYP3A and ABCB1 in Relation to Population Pharmacokinetics of Docetaxel , 2006, Clinical Cancer Research.

[8]  F. Goldwasser,et al.  Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphisms , 2006, Clinical pharmacology and therapeutics.

[9]  C. Hudis,et al.  Incidence of chemotherapy‐induced, long‐term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane , 2005, Cancer.

[10]  Andrew D. Johnson,et al.  Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability , 2005, Pharmacogenetics and genomics.

[11]  Y. Liou,et al.  C825T polymorphism in the human G protein beta3 subunit gene is associated with long-term clozapine treatment-induced body weight change in the Chinese population , 2005, Pharmacogenetics and genomics.

[12]  L. Benet,et al.  P-glycoprotein (P-gp/MDR1)-Mediated Efflux of Sex-Steroid Hormones and Modulation of P-gp Expression In Vitro , 2004, Pharmaceutical Research.

[13]  Conrad C. Huang,et al.  Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. , 2003, Pharmacogenetics.

[14]  B. Goh,et al.  Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Kasuga,et al.  Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects , 2002, Clinical pharmacology and therapeutics.

[16]  Jacques Fellay,et al.  Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study , 2002, The Lancet.

[17]  Mary V. Relling,et al.  Pharmacogenetics and cancer therapy , 2001, Nature Reviews Cancer.

[18]  K. Audus,et al.  Modulation of P-glycoprotein activity in Calu-3 cells using steroids and beta-ligands. , 2001, International journal of pharmaceutics.

[19]  M. Fromm,et al.  The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. , 2001, Pharmacogenetics.

[20]  J. Kigawa,et al.  Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. , 2001, The Journal of pharmacology and experimental therapeutics.

[21]  U. Brinkmann,et al.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Verweij,et al.  Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  A. Schinkel,et al.  The physiological function of drug-transporting P-glycoproteins. , 1997, Seminars in cancer biology.

[24]  K. Paull,et al.  P-glycoprotein substrates and antagonists cluster into two distinct groups. , 1997, Molecular pharmacology.

[25]  T. Fojo,et al.  Steroid transport, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells , 1996 .

[26]  D. Cohen,et al.  Progesterone regulates the murine multidrug resistance mdr1b gene. , 1993, The Journal of biological chemistry.

[27]  G. Montay,et al.  Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method. , 1992, Journal of chromatography.

[28]  D. Housman,et al.  Multidrug resistance gene expression is controlled by steroid hormones in the secretory epithelium of the uterus , 1990, Molecular reproduction and development.

[29]  Robert,et al.  Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus. , 1989, The Journal of biological chemistry.

[30]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[31]  L B Sheiner,et al.  Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  T. Fojo,et al.  Steroid treatment, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells. , 1996, Biochemistry.